tiprankstipranks
Advertisement
Advertisement

PVLA Stock Latest News

Palvella Therapeutics Adds Industry Veteran to Board
Company AnnouncementsPalvella Therapeutics Adds Industry Veteran to Board
3d ago
8K
PVLA
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
PremiumThe Fly
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
3d ago
PVLA
SVRA
Palvella submits first rolling new drug application to FDA for Qtorin
PremiumThe Fly
Palvella submits first rolling new drug application to FDA for Qtorin
4d ago
PVLA
FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin
PremiumThe Fly
FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin
11d ago
PVLA
Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership
PremiumCompany Announcements
Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership
17d ago
8K
PVLA
Palvella Therapeutics completes Qtorin pre-new drug application meeting with FDA
PremiumThe FlyPalvella Therapeutics completes Qtorin pre-new drug application meeting with FDA
30d ago
PVLA
Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program
Premium
The Fly
Palvella Therapeutics issued patent by USPTO for Qtorin pitavastatin program
1M ago
PVLA
Buy Rating Reiterated on Palvella as QTORIN Data Strengthen and $227 Price Target Remains Unchanged
Premium
Ratings
Buy Rating Reiterated on Palvella as QTORIN Data Strengthen and $227 Price Target Remains Unchanged
1M ago
PVLA
Fein Reiterates Buy on PVLA, Maintains $270 Price Target on Strong QTORIN Rapamycin Data and Clear Regulatory Path
PremiumRatings
Fein Reiterates Buy on PVLA, Maintains $270 Price Target on Strong QTORIN Rapamycin Data and Clear Regulatory Path
1M ago
PVLA
Palvella Reports Positive Phase 3 Data for QTORIN
PremiumCompany Announcements
Palvella Reports Positive Phase 3 Data for QTORIN
1M ago
8K
PVLA
Palvella Therapeutics announces new data from SELVA, TOIVA studies
PremiumThe Fly
Palvella Therapeutics announces new data from SELVA, TOIVA studies
1M ago
PVLA
Palvella Unveils Promising Phase 2 Data for QTORIN
PremiumCompany Announcements
Palvella Unveils Promising Phase 2 Data for QTORIN
2M ago
8K
PVLA
Palvella Therapeutics announces new data from TOIVA trial of Qtorin
PremiumThe FlyPalvella Therapeutics announces new data from TOIVA trial of Qtorin
2M ago
PVLA
Palvella Therapeutics Upgrades Listing to Nasdaq Global Market
Premium
Company Announcements
Palvella Therapeutics Upgrades Listing to Nasdaq Global Market
2M ago
8K
PVLA
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
Premium
Ratings
Analyst Initiates Buy on Palvella Therapeutics, Citing Differentiated QTORIN Platform and $1B+ Long‑Term Revenue Potential
2M ago
PVLA
Palvella Therapeutics initiated with an Overweight at Stephens
PremiumThe Fly
Palvella Therapeutics initiated with an Overweight at Stephens
2M ago
PVLA
Palvella Therapeutics reports Q1 EPS ($1.20) vs. (74c) last year
PremiumThe Fly
Palvella Therapeutics reports Q1 EPS ($1.20) vs. (74c) last year
2M ago
PVLA
Palvella Highlights QTORIN Progress and Financing in Q1 Update
PremiumCompany Announcements
Palvella Highlights QTORIN Progress and Financing in Q1 Update
2M ago
8K
PVLA
Palvella Therapeutics doses first patients in LOTU trial
PremiumThe Fly
Palvella Therapeutics doses first patients in LOTU trial
2M ago
PVLA
Palvella Therapeutics Adds Independent Dermatology Expert to Board
PremiumCompany AnnouncementsPalvella Therapeutics Adds Independent Dermatology Expert to Board
3M ago
8K
PVLA
Palvella Showcases QTORIN Platform Momentum and Commercial Readiness
Premium
Company Announcements
Palvella Showcases QTORIN Platform Momentum and Commercial Readiness
3M ago
8K
PVLA
3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
3M ago
KOD
PVLA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >